BI 1839100 / Boehringer Ingelheim - LARVOL DELTA

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=85 | Terminated | Sponsor: Boehringer Ingelheim | Trial completion date: Jul 2026 ➔ Sep 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jul 2026 ➔ Sep 2025; Sponsor decision

Trial completion date • Trial primary completion date • Trial termination • Cough • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body (clinicaltrials.gov) - P1 | N=8 | Terminated | Sponsor: Boehringer Ingelheim | Trial completion date: Nov 2024 ➔ Sep 2025

Trial completion date

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=85 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting | N=230 ➔ 85

Enrollment change • Enrollment closed • Cough • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body (clinicaltrials.gov) - P1 | N=8 | Terminated | Sponsor: Boehringer Ingelheim | Trial completion date: Sep 2025 ➔ Nov 2024

Trial completion date

A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body (clinicaltrials.gov) - P1 | N=8 | Terminated | Sponsor: Boehringer Ingelheim | Trial completion date: Dec 2025 ➔ Sep 2025 | Suspended ➔ Terminated; Company decision

Trial completion date • Trial termination

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=230 | Recruiting | Sponsor: Boehringer Ingelheim | Trial primary completion date: Mar 2026 ➔ Jul 2026 | Trial completion date: Mar 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Cough • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Proof of Pharmacology, Safety, and Pharmacokinetics of the Novel TRPA1 Antagonist BI 1839100: A Randomized, Placebo-Controlled, Parallel Group, First-In-Human Study in Healthy Male Participants. (PubMed, Clin Transl Sci) - "No significant imbalance in occurrence of adverse events was detected between single doses of BI 1839100 up to 300 mg and placebo, and PK profiles were dose-proportional in the 40-300 mg range. BI 1839100 demonstrated a dose-dependent inhibitory effect on DBF after the AITC skin challenge, indicating TRPA1-targeted pharmacological activity and potentiating BI 1839100 for further clinical development for a broad range of TRPA1 antagonistic applications."

Clinical • Journal • P1 data • PK/PD data

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=230 | Recruiting | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Recruiting

Enrollment open • Cough • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=230 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Cough • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=230 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Aug 2025 ➔ Mar 2026 | Trial primary completion date: Jul 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Cough • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body (clinicaltrials.gov) - P1 | N=8 | Suspended | Sponsor: Boehringer Ingelheim | Trial completion date: Dec 2024 ➔ Oct 2025 | Active, not recruiting ➔ Suspended

Trial completion date • Trial suspension

A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body (clinicaltrials.gov) - P1 | N=8 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting | N=16 ➔ 8

Enrollment change • Enrollment closed

A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=230 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Cough • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood (clinicaltrials.gov) - P1 | N=67 | Completed | Sponsor: Boehringer Ingelheim | Recruiting ➔ Completed

Trial completion

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=230 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P2 trial • Cough • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Boehringer Ingelheim | N=40 ➔ 58

Enrollment change

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003) (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Boehringer Ingelheim | Recruiting ➔ Completed

Trial completion

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003) (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003) (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (clinicaltrials.gov) - P1 | N=104 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (clinicaltrials.gov) - P1 | N=104 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial